Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:306-313.

Slides:

Advertisements

Similar presentations

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Advertisements

Update on Anti-platelets Gabriel A. Vidal, MD Vascular Neurology Ochsner Medical Center October 14 th, 2009.

Trial profile Fox K et al. Lancet 2008;372:

Trial Identification, Inclusion, and Exclusion Krista M. Dale et al, JAMA. 2006; 295:

Women’s Health Study: Vitamin E in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Julie E. Buring.

Women's Health Study: Low-Dose Aspirin in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Dr.

1 Therapies Not Indicated Andrew P. DeFilippis, Ty J. Gluckman, James Mudd, Catherine Campbell, Gregg Fonarow & Roger S. Blumenthal.

A Randomized Trial of a Multivitamin in the Prevention of Cardiovascular Disease in Men: The Physicians’ Health Study II HD Sesso, WC Christen, V Bubes,

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.

ACTIVE Clopidogrel plus Aspirin versus Aspirin in Patients Unsuitable for Warfarin.

Baseline Characteristics of Individuals From the General Population by Quartiles of Triglyceride Levels a Børge G. Nordestgaard, et al. JAMA 2007;298:

Flow of Participants Through the Trial David J. A. Jenkin et al. JAMA 2008;300:

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

The Relative Safety and Efficacy of Clopidogrel in Women and Men: A Sex-Specific Meta-Analysis Jeffrey S. Berger, Deepak L. Bhatt, Christopher P. Cannon,

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

Age-standardized mortality from ischaemic heart disease in European regions (men; age group years; year 2000) J Muller-Nordhorn, et al. Eur Heart.

Hsia J et al. J Am Coll Cardiol 2011;57: Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:

Flow Diagram of Identification of Randomized Trials for Inclusion Goran Bjelakovic, et al. JAMA. 2007;297:

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

Fat or Low-fat? Anwar T. Merchant ScD, MPH, DMD Department of Epidemiology and Biostatistics.

Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Aspirin for the Prevention of Cardiovascular Events.

Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Low-Dose Aspirin for Primary Prevention of Cardiovascular.

The SYMPHONY Trial Reference Reddan DN, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial.

Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis Jeffrey S. Berger, MD, MS, David L. Brown, MD, Richard C. Becker, MD The.

Date of download: 6/21/2016 From: Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services.

Date of download: 6/21/2016 From: Aspirin, Statins, or Both Drugs for the Primary Prevention of Coronary Heart Disease Events in Men: A Cost–Utility Analysis.

Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011CLINICAL PERSPECTIVE by Harlan M. Krumholz, Sharon-Lise T.

Discontinuation of medication after nonfatal event: MI

Copyright © 2012 American Medical Association. All rights reserved.

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis Stavros Stavrakis, MD The American Journal.

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

LEADER trial: Primary Outcome

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

Markov model structure

Comparison of Triflusal and Aspirin for Prevention of Vascular Events in Patients After Cerebral Infarction by Jordi Matías-Guiu, José M. Ferro, José Alvarez-Sabín,

ASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular disease Jane Armitage.

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

US Preventive Services Task Force. Ann Intern Med 2009;150:

Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease Nina Raju, MD, MsC, Magdalena Sobieraj-Teague, MBBS, Jack Hirsh, MD,

Relative risk of major events with atenolol vs placebo

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

BRAVO-3 Trial design: Patients undergoing transfemoral TAVR were randomized in a 1:1 fashion to bivalirudin or UFH. They were followed for 30 days. Results.

Potential mechanisms whereby statins may reduce the risk of stroke

Baseline Characteristics of Cardiovascular Risk Factors and Selected Dietary Variables in a Cohort of 22,881 Men and 35,091 Women to Quintile of Fish Intakes.

Relative risks of clinical events for primary and secondary prevention with selected drugs Thomas A Gaziano, et al. Lancet 2006; 368:

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Figure 1 Relationships between magnitude of antithrombotic benefit vs

Berger JS, et al. JAMA 2009;301:

Flow of Patients Through Trial

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

Study Participant Flow

Flow Diagram of the Trial Selection Process

Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal.

(A) Meta-analysis of repeat revascularisation in randomised trials.

Baseline Characteristics of the Subjects*

Women’s Health Study: Baseline Characteristics Part 1

MATCH Results: Implications for the Internist

Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:

Forest plots of randomised controlled trials and propensity score matched studies examining outcomes between patients taking proton pump inhibitor (PPIs)

Characteristics of included studies

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Comparison of Baseline Characteristics by Primary End Point

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Christian Madelaire et al. JCHF 2018;6:

Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Meta-analysis of trials examining the effects of aspirin on risk of CVD events in patients with diabetes. Meta-analysis of trials examining the effects.

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

Presentation transcript:

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

Design of Trials Included in the Meta-analysis Jeffrey S. Berger et al, JAMA. 2006;295:

Characteristics of Men and Women Included in Trials of Aspirin for the Primary Prevention of Cardiovascular Disease* Jeffrey S. Berger et al, JAMA. 2006;295:

Effect of Aspirin Treatment on the Primary Prevention of Major Cardiovascular Events and Myocardial Infarction Jeffrey S. Berger et al, JAMA. 2006;295:

Effect of Aspirin Treatment on the Primary Prevention of Stroke, Ischemic Stroke, and Hemorrhagic Stroke Jeffrey S. Berger et al, JAMA. 2006;295:

Effect of Aspirin Treatment on the Primary Prevention of Cardiovascular Mortality and Total Mortality Jeffrey S. Berger et al, JAMA. 2006;295:

Effect of Aspirin Treatment on Major Bleeding Jeffrey S. Berger et al, JAMA. 2006;295: